Omalizumab
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Drug Allergy
Conditions
Drug Allergy
Trial Timeline
Jul 1, 2014 → Dec 1, 2017
NCT ID
NCT02118987About Omalizumab
Omalizumab is a phase 1 stage product being developed by Novartis for Drug Allergy. The current trial status is completed. This product is registered under clinical trial identifier NCT02118987. Target conditions include Drug Allergy.
What happened to similar drugs?
8 of 15 similar drugs in Drug Allergy were approved
Approved (8) Terminated (3) Active (5)
✅Polyene phosphatidylcholine injection 930 mg QD + Magnesium Isoglycyrrhizinate injection 200 mg QDHaisco Pharmaceutical GroupApproved
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (18)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05424523 | Pre-clinical | Completed |
| NCT05157087 | Pre-clinical | Completed |
| NCT04037176 | Approved | Completed |
| NCT02550106 | Approved | Completed |
| NCT02329223 | Phase 3 | Completed |
| NCT02262130 | Phase 2 | Completed |
| NCT02118987 | Phase 1 | Completed |
| NCT02023151 | Approved | Completed |
| NCT01328886 | Phase 3 | Completed |
| NCT01155700 | Phase 3 | Completed |
| NCT00500539 | Phase 3 | Completed |
| NCT00264849 | Approved | Completed |
| NCT00180011 | Phase 2/3 | Completed |
| NCT00639691 | Approved | Completed |
| NCT00226200 | Pre-clinical | Terminated |
| NCT00482248 | Phase 3 | Completed |
| NCT00482508 | Phase 3 | Completed |
| NCT00046748 | Phase 3 | Completed |
Competing Products
20 competing products in Drug Allergy